Amgen (NSDQ:AMGN) announced today that it is set to acquire Five Prime Therapeutics (NSDQ:FPRX) for approximately $1.9 billion. Thousand Oaks, Calif.-based Amgen will acquire South San Francisco-based Five Prime for $38 per share in cash, reaching the equity value of approximately $1.9 billion, according to a news release. Get the full story at our sister site, Drug Delivery […]
Oncology
Q BioMed wins federal contract for bone cancer drug
Q BioMed (OTCQB:QBIO) announced today that it signed an agreement for its Strontium89 drug to be included on the Federal Supply Schedule (FSS). New York-based Q BioMed’s agreement with the U.S. government provides U.S. veterans and other federal government agencies and eligible patients access to Strontium89, a treatment for metastatic bone pain related to common cancers, […]
Elekta names permanent CFO
Elekta (STO:EKTA B) today said it has appointed Johan Adebäck as chief financial officer, effective immediately. Adebäck has served as the acting chief financial officer since June of last year. He was previously the group treasurer of the company since 2004, where he was responsible for treasury, taxes, customer financing, operations accounting and customer credit risk. […]
Grail, Quest Diagnostics to collaborate on Galleri multi-cancer early detection blood test
Grail announced that it entered into an agreement with Quest Diagnostics (NYSE:DGX) to collaborate on Grail’s Galleri multi-cancer blood test. Quest Diagnostics is slated to provide phlebotomy services in support of the Galleri multi-cancer early detection blood test, according to a news release. Menlo Park, Calif.-based Grail completed enrollment for the Pathfinder prospective study of Galleri in […]
Grail to debut multi-cancer blood test in Q2
Grail announced today that it expects to introduce its Galleri multi-cancer early detection blood test in the second quarter of 2021. Menlo Park, Calif.-based Grail completed enrollment for the Pathfinder prospective study of Galleri in clinical practice just last month, according to a news release. The 6,600-participant, multi-site, international study under an FDA investigational device […]
Delcath completes $22.2M offering
Delcath Systems (OTC:DCTH) announced that it completed an underwritten public offering of common stock worth approximately $22.2 million. New York-based Delcath’s offering includes nearly 1.7 million shares of its common stock at a public offering price of $13.25 per share, bringing the gross proceeds before deductions to approximately $22.2 million, according to a news release. The […]
Olympus buys Veran Technologies for $340M
Olympus (TYO:7733) announced today that it entered into an agreement to acquire Veran Medical Technologies for up to $340 million. St. Louis, Mo.-based Veran Medical develops advanced medical devices specializing in interventional pulmonology, including navigation products to develop solutions for improved diagnosis of peripheral lung cancer, according to a news release. The acquisition by Olympus is […]
BREAKING: Johnson & Johnson finally unveils its new robot-assisted surgery system
Johnson & Johnson (NYSE:JNJ) today shared details on its surgical robotic platform that it says offers unrivaled flexibility and control compared to the rest of the market. The new system is designed with six arms to provide more control and flexibility in surgery, while its arms will be integrated into the operating table. Additionally, the platform […]
Novocure closes $575M offering
NovoCure (NSDQ:NVCR) announced that it closed its previously announced offering of $575 million in 0% convertible senior notes. The notes, due in 2025, are set to bring in net proceeds of approximately $558.4 million after the initial purchasers exercised full their option to purchase an additional $75 million in notes, according to a news release from […]
Exact Sciences to acquire Thrive for $2.15B
Exact Sciences (NSDQ:EXAS) announced today that it is acquiring cancer detection tech developer Thrive Earlier Detection for $2.15 billion. Under the agreement, Thrive will receive the total consideration of up to $2.15 billion, which includes $1.7 billion payable at closing, comprised of 65% of Exact Sciences common stock and 35% in cash, according to a […]
GE Healthcare debuts breast cancer tech
GE Healthcare (NYSE:GE) announced today that it made the Serena Bright biopsy technology available in the U.S. Chicago-based GE Healthcare touts Serena Bright as the industry’s first contrast-enhanced guided biopsy solution, according to a news release. The technology is designed to help clinicians and patients in the fight against breast cancer. Serena Bright received FDA 510(k) […]
